Prot # VX11-950-117: A 2-Part, Open-Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Chronically Infected with Genotype 1 Hepatitis C Virus Following Liver Transplantation

Project: Research project

Project Details

StatusFinished
Effective start/end date5/14/12 → 5/14/15

Funding

  • Vertex Pharmaceuticals Incorporated (Prot # VX11-950-117)